SynthesisJournal of cellular physiology2019
Prognostic and clinicopathological significance of Cks1 in cancer: Evidence from a meta-analysis.
Synthesis in Journal of cellular physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.
- Clinicopathological and Prognostic Significance of Ubiquitin-Specific Protease 39 Overexpression in solid Cancers: A Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2023Pooled it
- Prognostic and clinicopathological significance of Cks1 in cancer: Evidence from a meta-analysis.Journal of cellular physiology · 2019Pooled it
- Functional Copy-Number Alterations as Diagnostic and Prognostic Biomarkers in Neuroendocrine Tumors.International journal of molecular sciences · 2024Article
- CKS1B as a potential target for prognostic assessment and intervention in pancreatic cancer and its role in abnormal proliferation and cellular phenotype through mediation of cell cycle signaling pathways.Saudi medical journal · 2024Article
- Regulation of microRNA miR-197-3p/CDC28 protein kinase regulatory subunit 1B (CKS1B) axis by Circular RNA hsa_circ_0000285 promotes glioma progression.Bioengineered · 2022Article
- Identification of CKS1B as a prognostic indicator and a predictive marker for immunotherapy in pancreatic cancer.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCyclin-dependent kinase subunit 1 (Cks1), as a highly conserved regulatory protein, has pleiotropic roles in cell cycle progression. As research progresses, increasingly more statistics show that Cks1 may be involved in the occurrence, development, and prognosis of a variety of tumors but the conclusions remain controversial. In addition, there has been no meta-analysis demonstrating the correlation between Cks1 and cancer. Therefore, this meta-analysis was performed to determine the prognostic and clinicopathological significance of Cks1 in various cancers.
methodsSystematic computer literature retrieval was conducted on the Web of Science, Embase, PubMed, CNKI, and Wanfang databases. Stata SE12.0 software was used in the quantitative meta-analysis. The hazard ratio (HR) and relative risk (RR) were pooled to assess the relationship between Cks1 expression and overall survival (OS), disease-free survival (DFS), and clinicopathological parameters.
resultsNineteen studies were included, totaling 2,224 participants. High expression of Cks1 was significantly correlated with worse OS (HR, 2.62; 95% confidence interval [CI], 2.18-3.14; p < 0.001) and poorer DFS (HR, 2.73; 95% CI, 1.83-4.08; p < 0.001). In addition, high expression of Cks1 was related to lymph node metastasis (RR, 1.59; 95% CI, 1.22-2.07; p = 0.001) and advanced T stage (RR, 1.14; 95% CI, 1.04-1.25; p = 0.005).
conclusionsHigh Cks1 expression predicted poorer prognosis and worse clinicopathological parameters in various cancers. Increased Cks1 could be a significant prognostic biomarker for poor survival in patients with various cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.